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ABSTRACT
Objective To compare the risk of non-fatal venous
thromboembolism in women receiving oral
contraceptives containing drospirenone with that in
women receiving oral contraceptives containing
levonorgestrel.
Design Nested case-control and cohort study.
Setting The study was based on information from
PharMetrics,aUnitedStatesbasedcompanythatcollects
information on claims paid by managed care plans.
Participants The study encompassed all women aged 15
to44yearswhoreceivedanoralcontraceptivecontaining
either drospirenone or levonorgestrel after 1 January
2002. Cases were women with current use of a study oral
contraceptive and a diagnosis of venous
thromboembolism in the absence of identifiable clinical
risk factors (idiopathic venous thromboembolism). Up to
four controls were matched to each case by age and
calendar time.
Main outcome measures Odds ratios comparing the risk
of non-fatal venous thromboembolism in users of the two
contraceptives; incidence rates and rate ratios of non-
fatal venous thromboembolism for users of each of the
study contraceptives.
Results186newlydiagnosed,idiopathiccasesofvenous
thromboembolismwereidentifiedinthestudypopulation
and matched with 681 controls. In the case-control
analysis, the conditional odds ratio for venous
thromboembolism comparing use of oral contraceptives
containing drospirenone with use of those containing
levonorgestrel was 2.3 (95% confidence interval 1.6 to
3.2). The incidence rates for venous thromboembolism in
the study population were 30.8 (95% confidence interval
25.6 to 36.8) per 100000 woman years among users of
oral contraceptives containing drospirenone and 12.5
(9.61 to 15.9) per 100000 woman years among users of
oral contraceptives containing levonorgestrel. The age
adjusted incidence rate ratio for venous
thromboembolism for current use of oral contraceptives
containingdrospirenonecomparedwiththosecontaining
levonorgestrel was 2.8 (2.1 to 3.8).
Conclusions The risk of non-fatal venous
thromboembolism among users of oral contraceptives
containingdrospirenoneseemstobearoundtwicethatof
users of oral contraceptives containing levonorgestrel,
after the effects of potential confounders and prescribing
biases have been taken into account.
INTRODUCTION
The first oral contraceptives were introduced in the
early 1960s and contained high doses of both oestro-
gen and progestogen. The doses of oestrogen were
foundtobeassociatedwithanincreasedriskofvenous
thromboembolism.
1 Over the subsequent years, oral
contraceptives containing smaller doses of oestrogen
and progestogen were introduced to the market in an
attempttoreducecardiovascularrisk.Thetypeof pro-
gestogen became the focus of discussion in the mid-
1990s, when concern was raised that women taking
third generation oral contraceptives (which contained
desogestrel or gestodene) were at an increased risk of
venous thromboembolism compared with those tak-
ing second generation oral contraceptives (which con-
tained levonorgestrel). Several studies found an
increased risk, whereas others argued that confound-
ing by indication or other biases could account for the
findings.
2-6 In the end, the consensus was that an
increased risk of venous thromboembolism existed in
users of third generation oral contraceptives. The risk
ofvenousthromboembolismwaslateralsofoundtobe
increased for use of oral contraceptives containing
cyproterone.
7 Thus, post-marketing surveillance to
monitor newer contraceptives as they are introduced
to the market is important, particularly for an estab-
lished risk such as venous thromboembolism.
Four published studies have examined the risk of
venous thromboembolism among women taking the
newer oral contraceptives containing drospirenone
compared with those taking other oral contraceptives
(including third generation oral contraceptives), with
inconclusive results.
8-11 Dinger et al and Seeger et al
found no association between venous thromboembo-
lism and drospirenone compared with “other” oral
contraceptives. Two more recent studies published in
the BMJ each found a small increased risk. A study by
Lidegaard et al reported a relative risk of 1.6 (95%
Boston Collaborative Drug
Surveillance Program, Boston
University School of Medicine, 11
Muzzey Street, Lexington, MA
02421, USA
Correspondence to: S S Jick
sjick@bu.edu
Cite this as: BMJ 2011;340:d2151
doi:10.1136/bmj.d2151
BMJ | ONLINE FIRST | bmj.com page 1 of 8confidence interval 1.3 to 2.1) comparing oral contra-
ceptives containing drospirenone with those contain-
inglevonorgestrel,andastudybyvanHylckamaVlieg
etalyieldedanoddsratioof1.7(0.7to3.9)forthesame
comparison.
All four studies included at least some non-
idiopathic cases of venous thromboembolism—that
is, cases for which another cause or strong risk factor
for venous thromboembolism was present, which
could result in attenuating an effect should it exist.
12
By not restricting the study to idiopathic cases, one
cannotcalculatetheriskattributabletooralcontracep-
tives among cases in the absence of other causes.
One study,
9 instead of using the reference exposure
most commonly used in recent studies of oral contra-
ceptives and venous thromboembolism (second
generation oral contraceptives containing levonorges-
trel), used a reference category that included women
who had taken third generation oral contraceptives.
These third generation oral contraceptives have been
shown to increase the risk of venous thromboembo-
lismcomparedwiththesecondgenerationoralcontra-
ceptives. Their inclusion in the reference category
would therefore dilute the estimate of risk.
Given the potential serious clinical consequences of
venous thromboembolisms and the growing popular-
ity of oral contraceptives containing drospirenone,
examining the association between venous throm-
boembolism and oral contraceptives containing
drospirenone compared with those containing levo-
norgestrelinstudiesthatavoidthelimitationsofearlier
publicationsisimportant.Wethereforedidastudythat
compared the risk of non-fatal venous thromboembo-
lism in women using oral contraceptives containing
drospirenonewiththatinwomenusingoralcontracep-
tives containing levonorgestrel. This study was
restricted to current users of one of these two oral con-
traceptives and to idiopathic cases of non-fatal venous
thromboembolism.
METHODS
Data resource
Data for this study came from the PharMetrics data-
base. PharMetrics is a United States based, ongoing
longitudinal database with information on around 55
millionpeoplegoingbackasfaras1995.Thedatabase
is made up of data contributed by managed care plans
throughouttheUnitedStatesandcontainsinformation
on paid claims for drugs, medical diagnoses, and pro-
cedures, as well as demographic information such as
the patient’s year of birth and sex and enrolment
details for each patient in the database. Prescriptions
fordrugsarecodedusingtheNationalDrugCodepro-
vided by the US Food and Drug Administration. Each
drug claim is entered as a separate entry and includes
informationonthespecificentitydispensed,thedateof
dispensing, the quantity dispensed, and the length of
the supply. All diagnoses are coded using the ICD-9
(International Classification of Diseases, 9th revision)
coding system. Procedure codes are also included in
the database, coded using the Current Procedural
Terminology-4 system. All events described above
are noted with the date on which the initial service
was delivered. This database has been used for many
previous studies of hormonal contraceptives in rela-
tion to venous thromboembolism and other cardio-
vascular outcomes.
13-17
We designed this study to take into account the eva-
luation of a relatively recently marketed drug and the
use of a comparison drug that has been marketed for
decades. We required that all cases and controls were
currentusersofeitherstudydrugafter1January2002;
drospirenone oral contraceptives were first marketed
in the United States in May 2001. Important variables
thatwecontrolledforinthedesignwereage,asusersof
thenewdrugmayhaveadifferentagedistributionthan
users of the older comparison drug, and calendar time
(thatis,thedateofdiagnosis),asthetwocontraceptives
will have highly different usage characteristics in rela-
tion to calendar time. We also explored duration of
use, which may be correlated with both drug use and
the risk of venous thromboembolism.
Base population
Wedidacase-controlstudynestedinthepopulationof
users of oral contraceptives containing drospirenone
or levonorgestrel, aged 15 to 44, in the PharMetrics
database updated to the end of December 2008. All
patients had to have filled at least one prescription for
a study drug after 1 January 2002. We excluded
women with risk factors for venous thromboembo-
lism, such as any history of cancer (other than non-
melanoma skin cancer), renal failure, chronic cardio-
vasculardisease,orinflammatoryorautoimmunecon-
ditions, from the base population.
Cases
Cases were women aged 15 to 44 years who were cur-
rent users of oral contraceptives containing drospire-
none or levonorgestrel and who had a first time
recorded claim for a clinically diagnosed deep vein
thrombosis or pulmonary embolism with a hospital
admission,a visitto the emergencyroom,or a positive
indicationofvenousthromboembolismfromdiagnos-
tic test results, and who subsequently received pro-
longed anticoagulation treatment. We included in the
study all cases with a first time diagnosis of venous
thromboembolism in 2002 or afterwards. Cases had
to have at least six months of medical history before
the diagnosis of venous thromboembolism (index
date) and had to be currently taking one of the study
drugs.Werestrictedthestudytowomencurrentlytak-
ingastudyoralcontraceptivebecausetheeffectoforal
contraceptives on the outcome, venous thromboem-
bolism, is acute and diminishes rapidly after the drug
isstopped.Wedeterminedoralcontraceptiveusefrom
the prescription claims data before the date of diagno-
sis of venous thromboembolism and defined it as hav-
ing a recorded claim for a prescription of a study
contraceptive whose filled use extended to within
30 days before the index date or beyond the index
date. Long term anticoagulation must have been
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trogen could be prescribed after the date of diagnosis,
indicating that the diagnosis of venous thromboembo-
lism was considered to be confirmed.
Torestrictthestudytoidiopathiccases,weexcluded
women from the case group if important clinical risk
factors for venous thromboembolism were present in
the 90 days before the index date. These included
severe lower limb injury, major surgery, severe
trauma, or pregnancy. An idiopathic case is one for
which no other proximate cause (other explanation)
exists for the venous thromboembolism. In cases for
which another known cause for their venous throm-
boembolism is present, such as recent surgery, the dis-
tribution of drug use is expected to represent the
distribution in the base population, and inclusion of
these non-idiopathic cases would dilute any true
increase in risk because the risk in the non-idiopathic
cases is expected to be most influenced by the other
proximate cause rather than by the oral contraceptive.
By restricting the study to idiopathic cases, one can
calculate the risk attributable to oral contraceptives
among cases in the absence of other causes.
To assess the eligibility of each potential case, we
reviewed each patient’s computer record with the
identity of the study oral contraceptive masked. We
achieved agreement on inclusion of women as cases
by consensus without knowledge of contraceptive use.
Controls
Wematchedfourwomenwhodidnothaveadiagnosis
ofvenousthromboembolismtoeachcasebyusingrisk
set sampling, by year of birth and the index date of the
case (calendar time). As with cases, all controls had to
be current users of one of the study contraceptives, to
have at least six months of enrolment in their health
plan before the index date (the event date of their
matched case), and to have used a study contraceptive
after 2002. We applied the same exclusion criteria to
controls as to cases. One of the authors reviewed the
computer record of each control.
Statistical methods
We generated descriptive characteristics of the cases
and controls, as well as distributions of risk factors by
contraceptive use in the controls to assess potential
confounding. We used conditional logistic regression
to analyse the matched case-control data. When strati-
fyingonvariablesotherthanthematchedfactorsofage
and index year, we had to break the matching and
therefore calculated odds ratios adjusted for age and
index year (instead of conditional odds ratios). We
evaluated duration of contraceptive use before the
index date, switching from a different hormonal con-
traceptive, obesity (if the record contained an ICD
code for obesity), other comorbidities, and number of
visits to a physician or emergency room in the six
monthsbeforetheindexdateaspotentialconfounders.
We used the 10% change in estimate rule to evaluate
confounding by comparing the crude odds ratio with
the odds ratio adjusted for each potential confounder
individually.
18 Variables that resulted in a 10% or
greater change in the odds ratio would have been con-
sidered to be material confounders; however, none of
the risk factors evaluated were confounders according
to this criterion.
We analysed the cohort data to estimate incidence
rates and 95% confidence intervals. Current person
time was accumulated from the first prescription of
study drug to the last prescription plus 45 days. If a
gapofgreaterthan100daysexistedintheprescription
fill dates, the person time accumulation stopped at the
last prescription before the gap, plus 45 days; person
timeaccumulationthenresumedatthenextrecordofa
prescription for a study drug. We estimated the inci-
dence rates and rate ratios by using Stata version 11.1
and Episheet.
19
We stratified the case-control analysis on age cate-
gory, index year, type of diagnosis (deep vein throm-
bosis versus pulmonary embolism), levonorgestrel
dose, and new versus continuous use of the study oral
contraceptive. We considered a woman to have a new
episode of use if she had a previous episode for an oral
contraceptive with a gapof at least 100 days before the
currentepisode or noprevious prescription foran oral
contraceptive andat least fourmonthsofrecordedhis-
tory in her computer record. Among women who had
anewepisodeofuseofthestudyoralcontraceptive,we
further stratified the analysis on whether the woman
had a previous episode of oral contraceptive use. We
classified all other women as users of unknown dura-
tion—that is, those whose current episode of study
drugbeganwithinfourmonthsofthestartoftheircom-
puter record. The four month period is based on the
finding that contraceptive prescriptions in the Phar-
Metrics database are written for no longer than three
monthsatatime.Awindowofatleastfourmonthsthus
provided evidence that the first identified prescription
was a new prescription and not a refill of an existing
prescription. We classified women with a prescription
recorded less than four months from the beginning of
their record as users of unknown duration, because we
could not determine with any confidence that the first
prescription in the database was for a new episode of
use. We defined duration of contraceptive use as the
time interval (in months) from the first use of an oral
contraceptive within the current episode (at the index
date) to the index date or as unknown. We defined a
womanasaswitcherifthepatient’srecordcontaineda
prescription for a hormonal contraceptive product
other than the one used at the index date in either the
sixmonthsorthe12monthsbeforetheindexdate.We
used SAS release 9.1 for analyses.
RESULTS
We identified 471 potentially eligible cases of venous
thromboembolism,ofwhichwedetermined285(61%)
to be non-idiopathic after blinded review of each
patient’s computer record. Our final study population
thus consisted of 186 cases of non-fatal venous throm-
boembolismand681controls(womenwithoutvenous
thromboembolism), matched by year of birth and
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cases and controls and also shows characteristics by
exposureamongcontrolsonly.Casesweremorelikely
tohaveadiagnosisofobesityintheirrecordandavisit
to an emergency department or a physician in the six
monthsbefore the index date. Users of oral contracep-
tives containing drospirenone were more likely than
users of those containing levonorgestrel to be younger
(aged under 30), to have a history of menstrual disor-
ders,tohaveashorterdurationofuse,andtohavehad
anewepisodeofuse(morethanfourmonthsofhistory
intheirrecordbeforetheirfirstprescriptionforastudy
oral contraceptive within the current episode or had a
previous episode of use).
Among the 186 cases of idiopathic venous throm-
boembolism, 121 (65%) women were currently using
an oral contraceptive containing drospirenone and 65
(35%) were using one containing levonorgestrel.
Amongthecontrols,313(46%)wereusinganoralcon-
traceptive containing drospirenone and 368 (54%)
were using one containing levonorgestrel. The unad-
justedmatchedoddsratioand95%confidenceinterval
for venous thromboembolism for oral contraceptives
containing drospirenone compared with those
containing levonorgestrel was 2.3 (95% confidence
interval1.6to3.2)(table 2).Afteradjustmentfordura-
tion of exposure, the odds ratio was virtually
unchanged(2.4,1.7to3.4).Neitherahistoryofobesity
nor switching from another hormonal contraceptive
had an effect on the odds ratio. When we stratified
cases on type of venous thromboembolism (deep
venous thrombosis compared with pulmonary embo-
lism)theresultsdidnotmateriallydiffer(oddsratio1.9
(1.1 to 3.2) for deep venous thrombosis and 2.6 (1.6 to
4.2) for pulmonaryembolism). Asusers of oral contra-
ceptives containing drospirenone were more likely to
have a new episode of use than were users of those
containing levonorgestrel, we stratified on new versus
unknown duration of use to evaluate possible bias or
modification of effect. We also stratified on calendar
year to evaluate whether potential bias related to the
recent marketing of oral contraceptives containing
drospirenonecouldexplain ourresults. Neither analy-
sis materially changed the results. The odds ratios for
venous thromboembolism, adjusted for age and index
year, were 2.5 (1.7 to 3.8) for women with a new epi-
sodeofuseand2.0(0.91to4.3)forthosewithunknown
duration of use (table 2). The conditional odds ratio
was 2.1 (1.1 to 4.0) among women with an index date
between 2002 and 2004 and 2.4 (1.6 to 3.6) among
thosewithanindexdatebetween2005and2008,com-
paring oral contraceptives containing drospirenone
and levonorgestrel.
As users of oral contraceptives containing drospire-
none were more likely to be younger (less than 30)
compared with women using oral contraceptives con-
taining levonorgestrel, we investigated for modifica-
tion of effect by age. Women under age 30 who used
oral contraceptives containing drospirenone had a
higher risk of venous thromboembolism than did
young women who used oral contraceptives contain-
ing levonorgestrel (odds ratio 3.7, 2.0 to 6.9). Among
womenaged30to39,theoddsratiowasnotmaterially
different from the effect in all women (1.9, 1.1 to 3.3).
Among women aged 40 to 44, the odds ratio was 1.4
(0.65 to 3.0); this age stratum contained fewer women.
Young women taking oral contraceptives containing
drospirenone were more likely to have a shorter dura-
tion oforal contraceptiveuse thanwere youngwomen
taking oral contraceptives containing levonorgestrel;
however, when we adjusted for duration in the analy-
sis, the conditional odds ratio increased to 4.0 (2.1 to
7.7) in the younger age stratum.
Users of oral contraceptives containing drospire-
none were slightly less likely to have a diagnosis of
obesity in this database (5.8% compared with 6.5% in
usersoforalcontraceptivescontaininglevonorgestrel).
When we added obesity to the model as a potential
confounder, the conditional odds ratio increased to
4.1 (2.1 to 7.9) among younger women. The condi-
tional odds ratios were virtually identical in the unad-
justed analyses and those adjusted for obesity for all
women in the study: adjusted odds ratio 2.3 (1.6 to
3.3). Finally, drospirenone treated women were more
likely to have a record of a menstrual disorder;
Table 1 |Descriptive characteristics by cases and controls and by exposure among controls.
Values are numbers (percentages)
Characteristic
Cases
(n=186)
Controls
(n=681)
Controls only
Drospirenone users
(n= 313)
Levonorgestrel users
(n= 368)
Age (years):
<30 77 (41) 281 (41) 153 (49) 128 (35)
30-39 77 (41) 279 (41) 111 (35) 168 (46)
40-44 32 (17) 121 (18) 49 (16) 72 (20)
Obesity 25 (13) 42 (6) 18 (6) 24 (7)
Hypertension 17 (9) 33 (5) 14 (4) 19 (5)
Coronary atherosclerosis 2 (1) 3 (<1) 2 (1) 1 (<1)
Other atherosclerosis 11 (6) 18 (3) 9 (3) 9 (2)
Hyperlipidaemia/
hypercholesterolaemia
22 (12) 44 (6) 24 (8) 20 (5)
Diabetes 6 (3) 23 (3) 11 (4) 12 (3)
Asthma 19 (10) 50 (7) 19 (6) 31 (8)
Endometriosis 2 (1) 8 (1) 5 (2) 3 (1)
Disorders of menstruation 44 (24) 152 (22) 84 (27) 68 (18)
Switch within 6 months 11 (6) 69 (10) 34 (11) 35 (10)
Switch within 12 months 24/148 (16) 96/502 (19) 46/222 (21) 50/280 (18)
Emergency room visits (≥1) 17 (9) 22 (3) 11 (4) 11 (3)
Physician visits (≥1) 29 (16) 60 (9) 31 (10) 29 (8)
Total duration (months):
<3 59 (32) 254 (37) 143 (46) 111 (30)
3-6 34 (18) 97 (14) 52 (17) 45 (12)
6-9 22 (12) 54 (8) 27 (9) 27 (7)
9-12 6 (3) 41 (6) 21 (7) 20 (5)
>12 42 (23) 137 (20) 29 (9) 108 (29)
Unknown 23 (12) 98 (14) 41 (13) 57 (15)
Typeoforal contraceptiveuse:
New users 144 (77) 517 (76) 264 (84) 253 (69)
Continuous users 42 (23) 164 (24) 49 (16) 115 (31)
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odds ratio of 3.7 (2.0 to 7.0) for women aged under 30
using oral contraceptives containing drospirenone
compared with womenunder 30 using oral contracep-
tivescontaininglevonorgestrel;theoddsratioadjusted
for menstrual disorder in the entire study population
was 2.3 (1.6 to 3.2). When we restricted the analysis to
women with no history of menstrual disorders or obe-
sity in the younger stratum, the odds ratio was 4.0 (1.8
to 8.8), adjusted for index year (40 cases in drospire-
none users and nine in levonorgestrel users).
Because of concern that the risk of venous throm-
boembolismmayberelatedtothedoseofethinylestra-
diolintheoralcontraceptive,werestrictedtheanalysis
to cases and controls who received an oral contracep-
tive containing either drospirenone or levonorgestrel
with 30 μg of ethinylestradiol (table 2). The duration
adjusted odds ratio was not materially different from
the main effect (2.2, 1.5 to 3.4). Among new users, we
furtherrestrictedtheanalysistowomenwhohadapre-
vious episode of oral contraceptive use that preceded
the episode at the index date to determine if the effect
wasmodifiedinre-starterscomparedwithwomenwith
no previous use recorded in their computer record.
The duration adjusted odds ratio in this stratum of
women was not materially different from the main
effect (2.6, 1.4 to 4.6). When we restricted the analysis
to women with no previous episode of use recorded,
the odds ratio was slightly higher (2.8, 1.5 to 5.2)
(table 2).
The study population contained 937408 women
who satisfied all the conditions for inclusion in this
study. These women contributed an estimated
392844 woman years for oral contraceptives contain-
ing drospirenone and 521824 woman years for oral
contraceptives containing levonorgestrel. The inci-
dence rates for venous thromboembolism in the
study population were 30.8 (95% confidence interval
25.6 to 36.8) per 100000 woman years among users of
oral contraceptives containing drospirenone and 12.5
(9.61to15.9)per100000womanyearsamongusersof
oralcontraceptivescontaininglevonorgestrel.Theage
adjusted incidence rate ratio for venous thromboem-
bolism comparing current use of oral contraceptives
containing drospirenone and levonorgestrel was 2.8
(2.1 to 3.8). The incidence rate of venous thromboem-
bolismincreasedwithincreasingageforbothoralcon-
traceptives. The incidence rate per 100000 woman
years among users of oral contraceptives containing
drospirenone was 24.8 (19.1 to 31.7) among women
aged 15-29 years, 39.0 (28.1 to 52.7) among those
aged 30-39, and 51.2 (29.3 to 83.2) among those aged
40-44. Among users of oral contraceptives containing
levonorgestrel,thecorrespondingincidencerateswere
5.39(2.94to9.05),18.7(13.0to26.0),and21.3(12.1to
34.5) (table 3).
DISCUSSION
These data provide evidence that current users of oral
contraceptives containing drospirenone have an
increased risk of non-fatal venous thromboembolism
compared with current users of oral contraceptives
containing levonorgestrel (adjusted odds ratio 2.4 (1.7
to 3.4); incidence rate ratio adjusted for age 2.8 (2.1 to
3.8)). We compared the risk of venous thromboembo-
lism in users of oral contraceptives containing drospir-
enone with that in users of oral contraceptives
containing levonorgestrel, because these second gen-
eration oral contraceptives have been shown to have
among the lowest risk of venous thromboembolism of
oral contraceptives on the market and have been used
in past studies of oral contraceptives in relation to
venousthromboembolism.
5-7101120Wealsodidanana-
lysis restricted to women who were “new” users of the
studyoralcontraceptive.Wedidthistoensurethatthe
morerecentavailabilityoftheoralcontraceptivescon-
tainingdrospirenonedidnotbiasthestudyfindings,as
all patients in the study had to have started the current
episode of oral contraceptive use after 1 January 2002,
soonafteroralcontraceptivescontainingdrospirenone
were first marketed. We also assessed the potential for
confounding or modification of effect by age and obe-
sity. Although we found some differences in effect in
younger women compared with women aged 30 and
older, the main finding that oral contraceptives con-
taining drospirenone conferred an increased risk of
venous thromboembolism compared with those con-
taining levonorgestrel remained. The increased risk
also remained when we adjusted for the effects of obe-
sity and history of menstrual disorders.
Table 2 |Odds ratios for venous thromboembolism in users of oral contraceptives containing
drospirenone compared with those containing levonorgestrel
Exposure No (%) cases No (%) controls
Crude* odds ratio
(95% CI)
Adjusted† odds
ratio (95% CI)
Overall
Levonorgestrel 65 (15) 368 (85) 1.0 1.0
Drospirenone 121 (28) 313 (72) 2.3 (1.6 to 3.2) 2.4 (1.7 to 3.4)
Levonorgestrel 20 users only
Levonorgestrel-20 20 (13) 131 (87) 1.0 1.0
Drospirenone 121 (28) 313 (72) 2.7 (1.6 to 4.7) 3.2 (1.8 to 5.5)
Levonorgestrel 30 users only
Levonorgestrel-30 45 (16) 237 (84) 1.0 1.0
Drospirenone 121 (28) 313 (72) 2.1 (1.4 to 3.1) 2.2 (1.5 to 3.4)
New episodes of use only
Levonorgestrel 42 (14) 253 (86) 1.0 1.0
Drospirenone 102 (28) 264 (72) 2.5 (1.7 to 3.8) 2.7 (1.7 to 4.1)
Users of unknown duration only
Levonorgestrel 23 (17) 115 (83) 1.0 1.0
Drospirenone 19 (28) 49 (72) 2.0 (0.91 to 4.3) 2.1 (0.96 to 4.7)
New episodes of use with no previous episode
Levonorgestrel 20 (17) 97 (83) 1.0 1.0
Drospirenone 52 (33) 106 (67) 2.7 (1.5 to 5.1) 2.8 (1.5 to 5.2)
New episodes of use with previous episode
Levonorgestrel 22 (12) 156 (88) 1.0 1.0
Drospirenone 50 (24) 158 (76) 2.3 (1.3 to 4.0) 2.6 (1.4 to 4.6)
*For overall analysis, crude odds ratio is a conditional odds ratio; for stratified analyses, crude odds ratios are
adjusted for age and index year.
†Also adjusted for duration.
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consistent with those of earlier studies of oral contra-
ceptives and venous thromboembolism. The rates
increased with increasing age and were of the same
magnitude as has been seen in previous studies.
561314
The incidence rate ratio estimated from these data was
similar to the odds ratio estimated from the case-con-
trol analysis, although it was slightly higher. We were
not able to control as precisely for age and calendar
time in the cohort study as in the case-control study,
which could explain some of the small difference in
the effect measures.
Although women who received oral contraceptives
containing drospirenone tended to have shorter dura-
tionofusecomparedwiththosewhoreceivedoralcon-
traceptivescontaininglevonorgestrel,bothcontrolling
for duration of use and stratifying by duration of use
did not materially change the effect estimates, so dura-
tion of use does not explain the increased risk in users
of drospirenone oral contraceptives. We also evalu-
ated whether material bias existed related to the more
recent availability of oral contraceptives containing
drospirenone compared with the older ones contain-
ing levonorgestrel. We found only a small difference
in the effect when we looked at the first several years
after marketing compared with the later years; the
effect was greater in the later years, suggesting that
bias related to prescribing of a newly marketed oral
contraceptive did not explain our finding.
Strengths and limitations
This epidemiological study used a case-control design
that ensured comparability between cases and the
comparison group at the time of the case event. Age
and calendar time were closely controlled—that is,
the controls were matched to cases on year of birth,
and the date at which exposure was determined (the
index date) was identical in cases and controls. This is
important, as oral contraceptives containing drospire-
none have been on the market for around 10 years
whereas those containing levonorgestrel have been
available for decades. We excluded patients with
chronic medical conditions such as cancer, coronary
artery disease, and autoimmune disease from the
study population. Although these conditions were not
commonly observed in this generally healthy young
population of contraceptive users, the exclusion of
such patients from the study population limits con-
cerns about selective prescribing of the study drug on
the basis of the presence of clinical risk factors (con-
founding by indication). More than 937000 women
who used one of the study drugs in our study popula-
tionprovidedinformationontheriskofvenousthrom-
boembolism in relation to oral contraceptives
containing drospirenone compared with levonorges-
trel. Because of the prospective nature of data collec-
tion, the information on contraceptive use was
recordedbeforethe outcomehadoccurred,alleligible
patients with the outcome were included, and the like-
lihood of correct diagnosis of venous thromboembo-
lism was increased by the documentation of long term
use of anticoagulants. Although some of the cases that
we included in the study may not have been true idio-
pathic cases, the misclassification is highly unlikely to
have been associated with contraceptive use, particu-
larlyasallcaseswerecurrentlyusingsomeoralcontra-
ceptiveattheindexdate.Mostwomeninthestudyhad
beenfillingprescriptionsforastudyoralcontraceptive
forseveralmonthsandasmuchasseveralyearsbefore
the index date, so misclassification of exposure is unli-
kely to have been a material factor in this study.
This study does have some limitations. Because we
couldnotvalidatethecasesinthisstudythroughreview
of primary records, we may have included some cases
thatwerenottruecasesofvenousthromboembolismor
that were not idiopathic cases, although any such mis-
classification would probably have been non-differen-
tial as we identified cases and controls without
knowledge of the contraceptive that they had been
using. Non-differential misclassification of a dichoto-
mous variable tends to bias results toward the null
and thus would not explain the increased risk found
in users of the oral contraceptives containing
drospirenone.
18 In addition, in the accompanying
study using the General Practice Research Database,
in which we were able to validate many cases, we
found a similar magnitude of effect.
20 We could not
evaluate the effect of smoking in this study, as it is not
regularly recorded in the PharMetrics database. How-
ever, smoking has not been a material confounder in
previous studies on the association between oral con-
traceptivesandvenousthromboembolism,
56norwasit
a confounder of the relation between oral contracep-
tivesandvenousthromboembolismintheaccompany-
ing General Practice Research Database study, which
wasable tocontrolforsmoking.
20Itisthusnotlikelyto
be a material confounder in this study. Neither height
nor weight was available in this study. Although body
mass index is independently associated with an
increased risk of venous thromboembolism, it has not
confounded the association between use of hormonal
contraceptives and venous thromboembolism in pre-
vious studies.
35-7 Furthermore, when we evaluated the
ICD-9 diagnosis for obesity, we found that obesity was
associated with an increased risk of venous
Table 3 |Incidence rates and incidence rate ratios for venous thromboembolism in users of
drospirenone and levonorgestrel oral contraceptives
Exposure Cases (n=186) Person years
Incidence rate (95% CI) per
100 000 person years
Incidence rate
ratio (95% CI)
Drospirenone/ethinylestradiol
Age <30 63 253 895 24.8 (19.1 to 31.7) 4.6 (2.6 to 8.2)
Age 30-39 42 107 701 39.0 (28.1 to 52.7) 2.1 (1.3 to 3.3)
Age 40-44 16 31 248 51.2 (29.3 to 83.2) 2.4 (1.2 to 4.8)
Levonorgestrel/ethinylestradiol 20 µ µgo r3 0µ µg
Age <30 14 259 522 5.39 (2.94 to 9.05) 1.0
Age 30-39 35 187 017 18.7 (13.0 to 26.0) 1.0
Age 40-44 16 75 284 21.3 (12.1 to 34.5) 1.0
Crude incidence rate ratio=2.5 (95% CI 1.8 to 3.3).
Incidence rate ratio adjusted for age=2.8 (95% CI 2.1 to 3.8).
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sion of obesity in the model with exposure did not
materially change the effect of contraceptive use, pro-
viding additional reassurance that obesity is not likely
to be an important confounder in this study. We found
thatusersoftheoralcontraceptivescontaininglevonor-
gestrelweremorelikelytobeobesethanweretheusers
of those containing drospirenone, so confounding by
obesity would not explain the increased risk for oral
contraceptives containing drospirenone. So, although
the diagnosis of obesity could be subject to reporting
bias, whereby only the most obese women have the
diagnosis recorded in the data, it would not explain
thestudyresult.Furthermore,wedidhaveinformation
on body mass index in the accompanying General
Practice Research Database study, and it did not mate-
rially confound the relation between the oral contra-
ceptives and venous thromboembolism.
20 As in the
PharMetricsdata,womenwhoreceivedoralcontracep-
tives containing levonorgestrel were more likely to
have a high body mass index than were users of those
containing drospirenone, but inclusion of body mass
indexinthelogisticregressionmodeldidnotmaterially
change the effect measure and did not account for the
increased risk of venous thromboembolism in users of
oralcontraceptivescontainingdrospirenonecompared
with levonorgestrel. Finally, we did not have informa-
tion on family history of venous thromboembolism in
thedatabase.Someselectionbiasamongwomenwitha
family history of venous thromboembolism is possible
but is unlikely to account for a material portion of the
effect, as idiopathic venous thromboembolism is not
common.
These data are derived from the PharMetrics data-
base, which contains health data for both insured and
Medicaid patients, although most are insured.
Although this study was carried out in women from
the United States, other studies in other countries
have provided no evidence that the association of oral
contraceptivewithvenousthromboembolismdiffersin
differentpopulations.
10112122Also,thisstudyevaluated
non-fatal venous thromboembolism and therefore did
not directly assess the risk of fatal venous thromboem-
bolism, although the effect in fatal and non-fatal cases
would be unlikely to differ greatly. Finally, we studied
theeffectoftwooralcontraceptivesonidiopathiccases
of venous thromboembolism, so this study does not
consider the risk in non-idiopathic cases.
Comparison with other publications
Among the four previously published studies that
examined the risk of venous thromboembolism in
women taking the newer oral contraceptives contain-
ing drospirenone compared with those taking other
oral contraceptives,
8-11 the studies by Dinger et al and
Seeger et al found no associations between drospire-
none and venous thromboembolism compared with
levonorgestrelandcomparedwith“other”oralcontra-
ceptives. In two more recently published studies by
Lidegaard et al and van Hylckama Vlieg et al, the
authors reported relative risks of 1.6 (1.3 to 2.1) and
1.7 (0.7 to 3.9) comparing oral contraceptives contain-
ingdrospirenonewiththosecontaininglevonorgestrel.
Women who were pregnant or postpartum were
excluded from these two more recent studies, as were
women with a previous venous thromboembolism.
Women with previous cancer or cardiovascular dis-
ease were further excluded from the Lidegaard study.
However, inclusion of other proximate causes such as
recentsurgeryandinjurycouldexplainthelowereffect
estimates in these studies compared with our study.
The Seeger and Dinger studies analysed all venous
thromboembolisms,includingpatientswithaprevious
venous thromboembolism, other risk factors, and
other proximate causes. These factors could explain
the null association found in these studies. The inclu-
sion of non-idiopathic cases of venous thromboembo-
lismhasbeenshowntoresultinattenuationofaneffect
should it exist.
1 As in our study, the risk of venous
thromboembolism in users of oral contraceptives con-
taining drospirenone was compared directly with the
risk in users of oral contraceptives containing levonor-
gestrel in the Lidegaard, van Hylckama Vlieg, and
Dinger studies. By contrast, the reference group in
the Seeger study included women using all other oral
contraceptives, including those containing cyproter-
one and desogestrel, which have been found to have
higher risks of venous thromboembolism compared
with the second generation oral contraceptives. Inclu-
sion of these women would have led to a higher risk in
the reference group and a lower relative risk for the
drospirenone oral contraceptive. Our study included
only current users of oral contraceptives containing
either levonorgestrel or drospirenone and avoided
including oral contraceptives carrying a higher risk in
the reference group.
Study implications
We found that, after adjustment for multiple potential
confounders and biases, current users of oral contra-
ceptives containing drospirenone were at around a
twofold increased risk of non-fatal idiopathic venous
thromboembolism compared with current users of
oral contraceptives containing levonorgestrel. These
findings support more recent studies that suggest that
drospirenone oral contraceptives are not as safe as
levonorgestrel oral contraceptives with respect to
venous thromboembolism and, in the absence of
other considerations, should not be the first choice in
oralcontraception.Aclosecomparisonofthemethods
of the four previously published studies and the two
new studies show possible explanations for the differ-
ing results.
Unanswered questions and future research
Additional studies with the same definitions of cases
and contraceptive use should be done to see if they
reproduce the same results, particularly now that the
drospirenone oral contraceptive has been on the mar-
ket for more than a decade. A systematic review of the
literature already published on this topic would be an
important addition to the literature at this time.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Previous studies that evaluated the risk of venous thromboembolism in users of oral
contraceptives containing drospirenone have found inconsistent results
Some studies have shown no increased risk compared with other oral contraceptives, and
other studies have shown small increased risks with drospirenone
WHAT THIS PAPER ADDS
Users of oral contraceptives containing drospirenone had around a twofold increased risk of
idiopathic venous thromboembolism compared with users of those containing
levonorgestrel, although the overall risk was low
The effects remained when prescribing biases and confounding were taken into account
Theincidencerateswere30.8(95%confidenceinterval25.6to36.8)and12.5(9.61to15.9)
per 100000 woman years among users of drospirenone and levonorgestrel oral
contraceptives
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